George Lasezkay

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA.

CollaGenex Pharmaceuticals, Inc. develops and markets innovative medical therapies to the dental and dermatology market. The company was founded in 1992 and is headquartered in Newtown, PA.

Acuity Pharmaceuticals, Inc. developed pharmaceutical products. The company used proprietary technology for the treatment and prevention of ophthalmic diseases. It developed drugs for age related macular degeneration and diabetic macular edema. Acuity Pharmaceuticals was founded in 2002 and was headquartered in Philadelphia, PA.

TheraVida, Inc. develops and commercializes therapeutic products that improve the lives of patients. The firm's products help to treatment of overactive bladder and urge urinary incontinence. It develops a portfolio of combination pharmaceutical products in the fields of urology and central nervous system disorders. The company was founded by Mehdi Paborji in 2005 and is headquartered in Chapel Hill, NC.

Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.

Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA.